{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-034700","form_type":"8-K","ticker":"CDT","cik":"0001896212","company_name":"CDT Equity Inc.","filed_at":"2023-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.026279+00:00","generated_at":"2026-06-10T07:11:53.105139+00:00","sec_items":["1.01","5.02","2.01","5.06","9.01","3.02","3.01","3.03","5.03","5.01","5.05","7.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Murphy Canyon completes de-SPAC merger with Conduit Pharmaceuticals Ltd.","bullets":["Transaction closed Sept 22, 2023; name changed to Conduit Pharmaceuticals Inc.; tickers CDT, CDTTW.","Post-combination shares outstanding: 72,418,316; 2,129,662 public shares redeemed at ~$10.84.","$20M PIPE financing from Nirland Limited: 2M units at $10/unit (1 share + 1 warrant).","Andrew Regan beneficially owns 62.9% (45.6M shares) of outstanding common stock.","Lock-up agreements for 180 days for certain former Conduit shareholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-034700","json":"https://secwatch.observer/filing/0001493152-23-034700.json","markdown":"https://secwatch.observer/filing/0001493152-23-034700.md","text":"https://secwatch.observer/filing/0001493152-23-034700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/0001493152-23-034700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:11:53.105139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31700489ce","claim":"David Tapolczay was appointed as Director at CDT Equity Inc..","evidence_excerpt":"David Tapolczay, Freda Lewis-Hall, James Bligh, Faith L. Charles, Jennifer I. McNealey, and Andrew Regan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/0001493152-23-034700-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"48174f4a1b","claim":"Faith L. Charles was appointed as Director at CDT Equity Inc..","evidence_excerpt":"David Tapolczay, Freda Lewis-Hall, James Bligh, Faith L. Charles, Jennifer I. McNealey, and Andrew Regan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/0001493152-23-034700-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4cbdaff937","claim":"Jennifer I. McNealey was appointed as Director at CDT Equity Inc..","evidence_excerpt":"David Tapolczay, Freda Lewis-Hall, James Bligh, Faith L. Charles, Jennifer I. McNealey, and Andrew Regan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/0001493152-23-034700-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"817940a6be","claim":"James Bligh was appointed as Director at CDT Equity Inc..","evidence_excerpt":"David Tapolczay, Freda Lewis-Hall, James Bligh, Faith L. Charles, Jennifer I. McNealey, and Andrew Regan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/0001493152-23-034700-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8e2bf8ac6d","claim":"Freda Lewis-Hall was appointed as Chair of the Board at CDT Equity Inc..","evidence_excerpt":"Ms. Lewis-Hall was appointed as Chair of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/0001493152-23-034700-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chair of the Board"}],"fact_type":"executive_change"},{"claim_id":"a60a8dfdb5","claim":"Freda Lewis-Hall was appointed as Director at CDT Equity Inc..","evidence_excerpt":"David Tapolczay, Freda Lewis-Hall, James Bligh, Faith L. Charles, Jennifer I. McNealey, and Andrew Regan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/0001493152-23-034700-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d43d448d57","claim":"David Tapolczay was appointed as Chief Executive Officer at CDT Equity Inc..","evidence_excerpt":"Effective upon the completion of the Business Combination, Mr. Tapolczay was appointed Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/0001493152-23-034700-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f2f5bd5530","claim":"Andrew Regan was appointed as Director at CDT Equity Inc..","evidence_excerpt":"David Tapolczay, Freda Lewis-Hall, James Bligh, Faith L. Charles, Jennifer I. McNealey, and Andrew Regan were appointed as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/0001493152-23-034700-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"20e808955e7030058b32d5255c676f3df49c94f0","claim":"CDT Equity Inc.: Company adopted amended and restated bylaws.","evidence_excerpt":"the Company adopted amended restated bylaws pursuant to an Amended and Restated Bylaws (the \"A&R Bylaws\")","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/0001493152-23-034700-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"860080986e66c2bd417492c16ebc9bcbadd8e747","claim":"CDT Equity Inc.: Company ceased to be a shell company as a result of the Business Combination.","evidence_excerpt":"As a result of the Business Combination, the Company ceased to be a shell company","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/0001493152-23-034700-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"shell status"}],"fact_type":"governance_change"},{"claim_id":"d6bd1b8e55483ef1998f8cb87e3034db3c62f2af","claim":"CDT Equity Inc.: Board adopted a new code of conduct effective upon the Closing Date.","evidence_excerpt":"Effective upon the Closing Date, in connection with the completion of the Business Combination, the Board adopted a new code of conduct","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/0001493152-23-034700-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"}],"fact_type":"governance_change"},{"claim_id":"f5308971d952b6b12edfd91b5037b2ca7eec9ad4","claim":"CDT Equity Inc.: Company amended and restated its certificate of incorporation effective as of the Closing Date.","evidence_excerpt":"In connection with the completion of the Business Combination, the Company amended and restated its certificate of incorporation, effective as of the Closing Date, pursuant to the Second A&R Certificate of Incorporation","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/0001493152-23-034700-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"0d86aefc49aa7480ce9c112d196ba441cf546b9e","claim":"CDT Equity Inc. underwent a change of control involving Conduit Pharmaceuticals Limited (Old Conduit) (closed 2023-09-22).","evidence_excerpt":"On September 22, 2023 (the “Closing Date”), the parties completed the Business Combination.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223034700/0001493152-23-034700-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Conduit Pharmaceuticals Limited (Old Conduit)"},{"label":"Closing","value":"2023-09-22"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}